Immunovant (IMVT) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings or view top-rated stocks.

11 analysts have issued 1-year price targets for Immunovant's shares. Their IMVT share price forecasts range from $5.00 to $32.00. On average, they predict the company's share price to reach $26.33 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts.

Immunovant's stock was trading at $17.75 at the start of the year. Since then, IMVT stock has increased by 19.7% and is now trading at $21.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IMVT earnings forecast.

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings data on Monday, May, 22nd. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.05.

ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Global X Guru Index ETF (GURU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), IQ Chaikin U.S. Small Cap ETF (CSML) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Immunovant's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (3.18%), State Street Corp (3.05%), BlackRock Inc. (3.02%), Logos Global Management LP (1.92%), Commodore Capital LP (1.11%) and Perceptive Advisors LLC (0.99%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends.

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMVT stock can currently be purchased for approximately $21.25.

Immunovant (NASDAQ:IMVT) has a market capitalization of $2.77 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com.